Campbell Soup Earnings: Stepped-Up Competition Amid Weak Consumer Spending Overshadows Strong Sales

""
Securities In This Article
Campbell Soup Co
(CPB)

The market soured on wide-moat Campbell Soup CPB even after it posted decent third-quarter marks—5% organic sales growth and 60 basis points of adjusted gross margin degradation to 30.9%—as seen by the 8% rout in shares. We attribute the reaction to concerns surrounding the competitive backdrop (which management suggested has gotten more promotional) and the state of consumer spending (which has weakened). But the firm appeared unmoved, reaffirming its outlook for 8.5%-10% sales growth and $2.95-$3.00 in adjusted EPS, which square with our 9.4% and $2.96 respective estimates before earnings. We don’t expect to alter our $58 fair value estimate (beyond time value) or our long-term forecast (low-single-digit sales and high-single-digit adjusted EPS growth) but now view shares as attractive, trading at a 20% discount to our valuation.

The fact that pricing was again a significant driver of both Campbell’s top line (up 12%) and gross margin performance (an 880-basis-point benefit) brings to light why the market moved against shares. To the extent that promotional spending reemerges within the industry as a tactic through which to gain market share (after remaining benign the past three years), Campbell (and its peers) won’t be able to tap the pricing lever in the near term. This would be further exacerbated if consumers increasingly tighten their purse strings. However, we never suspected pricing was a limitless well. Rather, Campbell is still pursuing other means to offset these pressures (namely, unearthing inefficiencies and dialing back discretionary spending) to dull the drain on profits. And despite facing elevated costs (an 8% hit in the quarter), management continues to invest in its brands—leveraging technology, data insights, and artificial intelligence to bring consumer-valued innovation to market in a timely fashion. Our forecast calls for it to direct 5% of sales (around $500 million) on average annually to research, development, and marketing through fiscal 2032.

The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.

More in Stocks

About the Author

Erin Lash, CFA

Sector Director
More from Author

Erin Lash, CFA, is a sector director, AM Consumer, for Morningstar*. In addition to leading the sector team, she covers packaged food and household and personal care companies. Beyond managing a team of nine analysts and associates covering an array of consumer firms, Lash also conducts fundamental analysis of 13 multi-billion-dollar market capitalization firms in the packaged food and household and personal care space.

Before joining Morningstar in 2006, Lash spent four years as an investment analyst covering retail, transportation, and technology firms for State Farm Insurance. In this capacity, Lash analyzed financial statements, business strategy, and fundamentals of owned companies and potential investments, presenting her recommendations based on this analysis to State Farm portfolio managers for ownership consideration.

Lash holds a bachelor’s degree in finance from Bradley University’s Foster College of Business. She also holds a master’s degree in business administration, with concentrations in accounting and finance, from the University of Chicago Booth School of Business. Lash has completed the Chartered Financial Analyst® designation. She ranked second in the food and tobacco industry in The Wall Street Journal’s annual “Best on the Street” analysts survey in 2013, the last year the survey was conducted.

* Morningstar Research Services LLC (“Morningstar”) is a wholly owned subsidiary of Morningstar, Inc

Sponsor Center